Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 23 papers were listed this time. Here's a handful:
Reed SD, Scales CD Jr, Stewart SB, et al. Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer. J Urol. 2011 Jan 14. [Epub ahead of print] PMID: 21239023 [PubMed - as supplied by publisher]Related citations
Cummins E, Asseburg C, Punekar YS, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health. 2011 Jan;14(1):15-23.PMID: 21211482
Pollock RF, Valentine WJ, Pilgaard T, et al. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. J Med Econ. 2011;14(1):36-46. PMID: 21192769
Dale W, Bilir SP, Hemmerich J, et al. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer. Med Care. 2011 Jan;49(1):59-66. PMID: 21150801
Soini EJ, García San Andrés B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol. 2011 Jan;22(1):215-23. PMID: 20627875
